Journal francais d'ophtalmologie · 2024
Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sahinoglu-Keskek N, Akkoyun I, Torer B, Cetinkaya B, Gülcan H, Yilmaz G, Oto S
Аннотация
OBJECTIVE: Anti-VEGF agents are used in the treatment of aggressive retinopathy of prematurity (A-ROP), which is a rapidly progressive form of retinopathy of prematurity (ROP). This study aimed to evaluate risk factors for the early reactivation after anti-VEGF therapy with intravitreal ranibizumab (IVR) injection.
METHODS: Consecutive cases of A-ROP were included in this retrospective study. Intravitreal ranibizumab (0.25mg, Lucentis, Novartis AG) was injected in all A-ROP cases as initial therapy. Probable risk factors were reviewed. A reactivation in 4 weeks or less was defined as "early", and greater than 4 weeks was defined as "late". Since reactivations were observed in Zone II in all cases, laser photocoagulation (LP) was performed as rescue therapy.
RESULTS: The study consisted of 16 patients with A-ROP, all of whom experienced reactivation. In 6 cases,reactivation was seen early (Group-E), and in 10 cases, reactivation was late (Group-L). The mean gestational age of Group-E and Group-L were 26.60 (±0.89) and 26.73 (±2.10) weeks respectively (P=0.9), and mean birth weights were 918 (±282) and 898 (±0188) grams respectively (P=0.8). Zone I ROP was seen at a higher rate in Group-E (83.3%) than Group-L (30%) (P=0.009). Total O2 treatment duration in Group-E was statistically significantly longer than Group-L (P=0.03). The mean value of platelet distribution width (PDW) in Group-E was statistically significantly higher (P=0.002).
CONCLUSIONS: In patients with A-ROP, extended duration of O2 therapy and high values of PDW might be factors predictive of early reactivation after intravitreal ranibizumab injection.
METHODS: Consecutive cases of A-ROP were included in this retrospective study. Intravitreal ranibizumab (0.25mg, Lucentis, Novartis AG) was injected in all A-ROP cases as initial therapy. Probable risk factors were reviewed. A reactivation in 4 weeks or less was defined as "early", and greater than 4 weeks was defined as "late". Since reactivations were observed in Zone II in all cases, laser photocoagulation (LP) was performed as rescue therapy.
RESULTS: The study consisted of 16 patients with A-ROP, all of whom experienced reactivation. In 6 cases,reactivation was seen early (Group-E), and in 10 cases, reactivation was late (Group-L). The mean gestational age of Group-E and Group-L were 26.60 (±0.89) and 26.73 (±2.10) weeks respectively (P=0.9), and mean birth weights were 918 (±282) and 898 (±0188) grams respectively (P=0.8). Zone I ROP was seen at a higher rate in Group-E (83.3%) than Group-L (30%) (P=0.009). Total O2 treatment duration in Group-E was statistically significantly longer than Group-L (P=0.03). The mean value of platelet distribution width (PDW) in Group-E was statistically significantly higher (P=0.002).
CONCLUSIONS: In patients with A-ROP, extended duration of O2 therapy and high values of PDW might be factors predictive of early reactivation after intravitreal ranibizumab injection.